Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,389,628 papers from all fields of science
Search
Sign In
Create Free Account
CAPOX Regimen
Known as:
CAPEOX Regimen
, Capecitabine-Oxaliplatin Regimen
A regimen consisting of capecitabine and oxaliplatin used as a treatment for advanced stage colorectal cancer. This regimen differs from a similar…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Colorectal Carcinoma
capecitabine
oxaliplatin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Y. Huang
,
S. Huang
,
+6 authors
Y. Deng
Zhonghua wei chang wai ke za zhi = Chinese…
2020
Corpus ID: 213191955
Objective: To investigate the feasibility and safety of sphincter-preserving surgery after neoadjuvant chemoradiotherapy (nCRT…
Expand
2019
2019
Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
J. Xu
,
Chengwu Tang
,
W. Feng
,
Y. Bao
,
Z. Chai
Medical Science Monitor
2019
Corpus ID: 195759295
Background Colorectal cancer (CRC) is considered to be a worldwide health problem because of its increasing incidence and…
Expand
2018
2018
Phase II Randomized Trial of Biweekly Bevacizumab, Capecitabine, Oxaliplatin and Irinotecan (BEV- CAPEOXIRI) Versus Triweekly Bevacizumab, Capecitabine and Oxaliplatin (BEV- CAPEOX) in Metastatic…
A. A. Ali
,
Mahmoud ABUL-MAKAREM
2018
Corpus ID: 210138988
AbstractBackground: Bevacizumab, Capecitabine and Oxaliplatin (BEV-CAPEOX) is an effective combination in patients with…
Expand
2016
2016
Activity and tolerance of biweekly CapeOx-cetuximab in 1st line therapy of metastatic colorectal cancer (mCRC): Relation to K-ras mutation status.
Y. Yuan
,
H. Ma
,
+7 authors
H. Hochster
Journal of Clinical Oncology
2016
Corpus ID: 39638714
e15018 Background: This novel q2w schedule trial combined oxaliplatin (Ox), flat dose capecitabine (Cape) and cetuximab(C) in…
Expand
Review
2014
Review
2014
Skin and maxillary sinus involvement of colon cancer
M. Akyol
,
L. Demir
,
+9 authors
M. Tarhan
Contemporary oncology
2014
Corpus ID: 6169377
Cutaneous and maxillary sinus metastases of malignancies are not frequent. The most common malignancies metastasizing to the skin…
Expand
2011
2011
Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.
Le Zhang
,
Ling-yun Wang
,
+7 authors
Yu-hong Li
Journal of B.U.ON. : official journal of the…
2011
Corpus ID: 31530618
PURPOSE Small bowel adenocarcinoma (SBA) is a rare malignancy, and most patients present with unresectable or metastatic disease…
Expand
2011
2011
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
S. Stintzing
,
L. Fischer von Weikersthal
,
+16 authors
V. Heinemann
British Journal of Cancer
2011
Corpus ID: 5099244
Background:The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens…
Expand
2008
2008
Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy
S. Kakolyris
,
J. Souglakos
,
+9 authors
V. Georgoulias
Oncology
2008
Corpus ID: 19709247
Background: To evaluate the efficacy and tolerance of capecitabine (CAP) given every other week and biweekly oxaliplatin (OX…
Expand
2008
2008
Primary Mucinous Adenocarcinoma of Appendix Treated with Chemotherapy and Radiotherapy: A Case Report
E. Topkan
,
Y. Polat
,
A. Karaoglu
Tumori
2008
Corpus ID: 38599543
A rare case of primary appendiceal mucinous adenocarcinoma is reported. The presenting signs and symptoms were suggestive of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE